With the fourth coming AML 1b results expected as early as June (Ann) a recap statements and events leading up to then follows.
On the phone conference last year, when asked, Dr. Seibi responded to the question of the combined efficacy results ( combined with chemo) that a good result would be around 40%.
Baseline (chemo alone) on this dreadful disease is around 20%, therefore the standard care.
PTX200 monotherapy 1a results pretty much matched this (exceptional result).., to which one must add the safety and side effects potential benefits that a patient I could only imagine could benefit strongly reduced.
With current pilots on the AML phase 2 currently being conducted as again using the words of the co-founder, the aim is to maximise safety and efficiency with dosages, yet more is not necessarily the case of better.
I for one am glad we have a two consecutive year top twenty scientist awarded head backed by a competent team.
On the other side of the strategic team is our management.
Our CEO (Steve) has on a couple of occasions suggested that ideally would not like to go to market (potential partners and or take overs ) to early a piece. Confidence is strongly implied here on many levels. Of course, that doesn’t mean that the market won’t come to PTX, especially if results so.
Exciting year(s) ahead for this gem.
As a wise fellow poster stated a year or so ago...., PTX may be the ride of a lifetime .
PTX Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
